Does a favorable TMAO, oxidized LDL, ADMA, hs-CRP, Lp-PLA2, and myeloperoxidase pattern suggest a low inflammatory and oxidative cardiometabolic signal?

A favorable profile across TMAO, oxidized LDL, ADMA, hs-CRP, Lp-PLA2 activity, and myeloperoxidase is directionally consistent with less adverse cardiometabolic inflammation, oxidative stress, endothelial dysfunction, and plaque-associated immune activity. It is best interpreted as supportive context rather than a validated “low-risk” composite.

Clinical and prognostic evidence

• hs-CRP has the strongest established role: elevated concentrations independently predict myocardial infarction, stroke, cardiovascular death, and peripheral arterial disease, though it measures systemic rather than vessel-specific inflammation.
• Higher TMAO is associated with major cardiovascular and cerebrovascular events in systematic-review/meta-analytic evidence, but renal function, diet, and assay variation materially affect interpretation.
• In stable coronary disease, elevated Lp-PLA2 remained independently associated with adverse cardiovascular outcomes after adjustment for traditional risk factors and hs-CRP. hs-CRP plus Lp-PLA2 modestly improved risk discrimination in a community cohort.
• In angiography patients, elevated myeloperoxidase (MPO) independently predicted cardiovascular mortality; MPO combined with CRP improved long-term mortality stratification.

Biological interpretation

• Lower TMAO is compatible with less unfavorable gut microbial–host metabolic signaling.
• Lower oxidized LDL and MPO are consistent with less oxidative lipoprotein modification and neutrophil/immune-vascular oxidative activity.
• Lower ADMA supports a more favorable endothelial nitric-oxide milieu, while lower Lp-PLA2 activity is compatible with less plaque-related lipid-inflammatory activity.

Clinical implications

• These markers assess partially overlapping but nonidentical pathways. Lp-PLA2 mass and activity are not interchangeable, and activity thresholds have population-dependent validation.
• This specific six-marker pattern has not been validated for treatment decisions or for establishing that active inflammation/oxidative stress is low across all pathways.

Bottom line

• A favorable panel plausibly supports a lower inflammatory–oxidative cardiometabolic signal, but it cannot exclude important cardiovascular risk or replace standard assessment of lipids, blood pressure, diabetes, and overall clinical risk.